相关实验视频

Updated: Jun 13, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

在三阴性乳腺癌和对免疫治疗的反应中,卡斯巴-1-依赖的空间性

Weiyue Zheng¹, Wanda Marini¹, Kiichi Murakami¹

¹Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Nature communications

|October 1, 2024

概括

雌激素受体α (ERα) 在三阴性乳腺癌 (TNBC) 中负面调节ETS1驱动的caspase-1. 卡斯巴酶-1抑制重塑瘤免疫微环境 (TIME) 并增强免疫疗法反应.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

瘤免疫微环境 (TIME) 的空间组织对于预测三阴性乳腺癌 (TNBC) 的结果和治疗反应至关重要.
一个免疫抑制的TIME,其特征是丰富的瘤相关巨细胞 (TAMs) 和少数CD8+T细胞,与TNBC的预后不佳相关,但潜在的调节机制仍然不清楚.

研究的目的:

在TNBC中阐明管理"时代"的监管机制.
研究ETS1驱动的caspase-1表达及其由雌激素受体α (ERα) 调节在塑造TNBC TIME中的作用.
确定改善TNBC免疫疗法反应的潜在治疗点.

主要方法:

在三阴性乳腺癌 (TNBC) 样本中分析瘤免疫微环境 (TIME).
研究雌激素受体α (ERα) 和ETS1对-1表达的调节作用.
使用小鼠模型研究ERα,ETS1,caspase-1和IL1β对TIME构成的功能影响.
评估caspase-1抑制对TIME的影响以及对免疫检查点封锁的反应.

主要成果:

对于IL1β处理和TAM招募至关重要的ETS1驱动的caspase-1表达,在TNBC中受到ERα的负调节.
瘤卡斯帕酶-1的升高与免疫抑制的TIME与增加的瘤前TAMs和CD8+T细胞排斥有关.
鼠标模型证实了ERα,ETS1,caspase-1和IL1β在确定TIME特征中的功能意义.
卡斯巴酶-1抑制成功诱导了免疫反应时间,并克服了对免疫检查点阻塞的抵抗力.

结论:

在ETS1驱动的caspase-1的ERα介导调节是TNBC中TIME的关键决定因素.
向caspase-1代表了一种有前途的治疗策略,用于重塑免疫抑制的TIME并提高TNBC中免疫治疗的疗效.
这项研究确定了一种新的,治疗上可向的机制,控制TNBC空间组织和免疫逃避.

更多相关视频

Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment

Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment

Published on: March 25, 2020

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...